Stock Events

Stock Events

OnKure Therapeutics 

$4.28
15
-$0.1-2.28% Today

Statistics

Day High
4.46
Day Low
4.25
52W High
4.75
52W Low
1.7
Volume
292,931
Avg. Volume
277,665
Mkt Cap
55.05M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.38
-1.17
-0.96
-0.74
Expected EPS
-0.7425
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-105.35MNet Income

Analyst Ratings

$27.00Average Price Target
The highest estimate is 27.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OKUR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, competing in the rare disease space similar to Reneo Pharmaceuticals.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics is involved in the development of genetic medicines for rare diseases, directly competing with Reneo Pharmaceuticals' focus on rare genetic disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, closely aligning with Reneo Pharmaceuticals' mission.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals works on RNAi therapeutics for the treatment of rare diseases, presenting a competitive approach to Reneo Pharmaceuticals' strategy.
Ionis Pharmaceuticals
IONS
Mkt Cap12.35B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, which places it in direct competition with Reneo Pharmaceuticals in the rare disease market.
PTC Therapeutics
PTCT
Mkt Cap5.7B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines for rare disorders, making it a competitor to Reneo Pharmaceuticals.
Galapagos NV
GLPG
Mkt Cap1.98B
Galapagos NV specializes in the discovery and development of small molecule medicines with novel modes of action, competing in the same innovative space as Reneo Pharmaceuticals.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is focused on developing gene-based medicines for serious diseases, including rare diseases, which places it in competition with Reneo Pharmaceuticals' focus on genetic disorders.

About

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Show more...
CEO
Dr. Nicholas A. Saccomano Ph.D.
Employees
46
Country
US
ISIN
US68277Q1058

Listings

XNAS
US
OKUR
BOATS
BOATS
OKUR.BOATS

0 Comments

Share your thoughts

FAQ

What is OnKure Therapeutics stock price today?▼
The current price of OKUR is $4.28 USD — it has decreased by -2.28% in the past 24 hours. Watch OnKure Therapeutics stock price performance more closely on the chart.
What is OnKure Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange OnKure Therapeutics stocks are traded under the ticker OKUR.
Is OnKure Therapeutics stock price growing?▼
OKUR stock has fallen by -0.23% compared to the previous week, the month change is a +25.88% rise, over the last year OnKure Therapeutics has showed a +35.87% increase.
What is OnKure Therapeutics market cap?▼
Today OnKure Therapeutics has the market capitalization of 55.05M
When is the next OnKure Therapeutics earnings date?▼
OnKure Therapeutics is going to release the next earnings report on May 12, 2026.
What were OnKure Therapeutics earnings last quarter?▼
OKUR earnings for the last quarter are -0.99 USD per share, whereas the estimation was -1.15 USD resulting in a +14.06% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is OnKure Therapeutics revenue for the last year?▼
OnKure Therapeutics revenue for the last year amounts to 0 USD.
What is OnKure Therapeutics net income for the last year?▼
OKUR net income for the last year is -105.35M USD.
How many employees does OnKure Therapeutics have?▼
As of April 09, 2026, the company has 46 employees.
In which sector is OnKure Therapeutics located?▼
OnKure Therapeutics operates in the Health Care sector.
When did OnKure Therapeutics complete a stock split?▼
The last stock split for OnKure Therapeutics was on October 07, 2024 with a ratio of 1:10.
Where is OnKure Therapeutics headquartered?▼
OnKure Therapeutics is headquartered in Boulder, US.